Pancreatic Tumor Imaging (2026)-W8-CGI0422-2026

Video Transcription

Video Summary

The lecture reviewed modern imaging of pancreatic cancer, emphasizing that pancreatic protocol multiphasic CT is the first-line test for diagnosis and staging. Key CT findings include a hypoattenuating, infiltrative mass, ductal obstruction, double-duct sign, and duct cutoff sign, which should prompt aggressive evaluation with MRI or endoscopic ultrasound. Dual-energy CT can improve tumor conspicuity, vascular delineation, and detection of small metastases, especially using low-keV monoenergetic and iodine images.<br /><br />Staging is based on resectability: resectable, borderline resectable, locally advanced, or metastatic disease. Accurate reporting of arterial and venous involvement is critical because it determines surgical planning, neoadjuvant therapy, and prognosis. Structured reporting templates were strongly endorsed, with shorter post-op templates suggested to improve workflow.<br /><br />The talk also highlighted common pitfalls in response assessment after neoadjuvant therapy, including difficulty distinguishing fibrosis from viable tumor, and the value of FDG-PET in equivocal cases. Other pitfalls included liver abscesses mimicking metastases and recurrent tumor versus benign post-surgical changes.<br /><br />Finally, the lecture covered emerging AI applications in pancreatic cancer: automated detection, cyst risk stratification, radiomics for early detection, body composition analysis for sarcopenia, opportunistic screening, and improved treatment allocation. Overall, imaging is central to diagnosis, staging, response assessment, and early detection efforts in pancreatic cancer.

Keywords

pancreatic cancer

pancreatic protocol CT

multiphase CT

dual-energy CT

resectability staging

structured reporting

FDG-PET

artificial intelligence